Table 1.
An overview of Phase 1 and 2 clinical trials regarding gene-based therapy for coronavirus disease 2019
| Status | Interventions | Population | Phase | Location | NCT number | |
|---|---|---|---|---|---|---|
| 1 | Recruiting | mRNA-1273 | 45 | 1 | •Emory Vaccine Center, The Hope Clinic, Decatur, Georgia, USA •National Institutes of Health Clinical Center – Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, USA •Kaiser Permanente Washington Health Research Institute Vaccines and Infectious Diseases, Seattle, Washington, USA |
NCT04283461 |
| 2 | Recruiting | Injection and infusion of LV-SMENP-DC vaccine and antigen-specific cytotoxic T cells | 100 | 1,2 | •Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China •Shenzhen Second People's Hospital, Shenzhen, Guangdong, China •Shenzhen Third People's Hospital, Shenzhen, Guangdong, China |
NCT04276896 |
| 3 | Recruiting | Pathogen-specific artificial antigen-presenting cells | 100 | 1 | •Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China | NCT04299724 |
| 4 | Active, not recruiting |
Recombinant novel coronavirus vaccine (adenovirus type 5 vector) |
108 | 1 | •Hubei Provincial Centre for Disease Control and Prevention, Wuhan, Hubei, China |
NCT04313127 |
| 5 | Recruiting | INO-4800 | 40 | 1 | •Center for Pharmaceutical Research, Kansas City, Missouri, USA •University of Pennsylvania, Philadelphia, Pennsylvania, USA |
NCT04336410 |
NCT, National Clinical Trial.